Regarding the reversible “exhaustion" of T cells by effective PD-1 blockade during chronic viral infection [38], a phase I clinical trial for single-dose humanized anti-PD-1 antibody in cancer patients was initiated. This evidence concerns the gene PDCD1 and viral infectious disease.